Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Monday, September 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acadia Pharmaceuticals has received a Notice of Allowance from the USPTO for its U.S. Patent Application No. 17/590,496, which covers weight-banded dosing of Trofinetide for treating Rett Syndrome. This patent is expected to be issued soon, extending protections until March 2041. This development enhances the company's market position and potential revenue from Trofinetide.

Market Sentiment Analysis

POSITIVE FACTORS

  • Patent protection extended to March 2041.
  • Notice of Allowance indicates strong patentability.
  • Potential for enhanced market exclusivity for Trofinetide.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
4.5%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrative

Frequently Asked Questions

What is the significance of the patent allowance?

The patent allowance extends protections for Trofinetide, enhancing market exclusivity.

How long is the patent protection for Trofinetide?

The patent protection for Trofinetide is extended to March 2041.

What is Trofinetide used to treat?

Trofinetide is used for the treatment of Rett Syndrome.

Who issued the Notice of Allowance?

The Notice of Allowance was issued by the United States Patent and Trademark Office.

ShareAdd on Google
Tags: ACAD Acadia Pharmaceuticals Trofinetide Rett Syndrome U.S. Patent patent protection
Last updated: Sep 28, 2026

Biotech snapshot

Cash runway
$956M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ACP-211Phase 2
Major Depressive Disorder (MDD) →

Catalyst track record

+45%
best trade around ACAD's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for ACAD.

See every catalyst's timing & PoA →